Action Alert: Help Secure New Cosponsors for the STAR Reauthorization Act
Today we join with our colleagues at other Alliance for Childhood Cancer member organizations in meeting with Congressional representatives to seek reauthorization of the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act. We invite you to support today's unified push for action by reaching out to your own Senators and Representative using our action alert.
About the STAR Act
The original STAR Act was signed into law in 2018 and authorized five years of funding at $30 million annually from 2019-2023. The STAR Act was celebrated as the most comprehensive childhood cancer legislation ever taken up by Congress. This legislation expands opportunities for childhood cancer research, improves efforts to identify and track childhood cancer incidences, and enhances the quality of life for childhood cancer survivors.
About the Reauthorization
As the STAR Act nears its expiration, please join us in seeking five more years of funding through the STAR Reauthorization Act (H.R.7630 / S.4120). Reauthorizing this landmark legislation for five more years will enable STAR Act programs to continue making a life-saving impact for the 16,000 children in the U.S. who are diagnosed with cancer every year and the more than 500,000 survivors who face a lifetime of health challenges due to their treatment.
Check the Cosponsor List
Before reaching out to your Members of Congress, take a moment to see if they are already a cosponsor of the bill. The 2022 bipartisan reauthorization bill currently has 17 cosponsors in the Senate and 41 in the House.
If your Members are already signed on, you can skip the sign-on ask and instead send them a quick tweet or message with your thanks! If they are not yet signed on, then use this alert to ask them to add their name as a cosponsor.
Thank you for joining us in this day of action during Childhood Cancer Awareness Month. Together, we're making big strides for children with cancer, survivors, and their families.